1Telliez A, Furman C, Pommery N, et al. Mechanisms leading to COX-2 expression and COX-2 induced umorigenesis: topical therapeutic strategies targeting COX-2 expression and activity[ J ]. Anticancer Agents Med Chem,2006, 6(3) :187 -208.
2Dalpiaz AS, Peterson D. Parecoxib: a shift in pain management? [J]. Expert Rev Neurother, 2004, 4(2) : 165 - 177.
3Hwang M, Kim HJ, Noh H J, et al. TGF-betal siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction[J]. Exp Mol Pathol, 2006, 81 (1) ,48 - 54.
6Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest, 2002,110(3) : 341-350.
7Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol, 2001,159(4) : 1465-1475.
8Zeisberg M, Kalmi R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med, 2004,82 (3) : 175-181.
9Croxtall JD, van Hal PT, Choudhury Q, et al. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol, 2002,135(2) :511-519.
10Copeland JW, Beammont BW, Merrilees MJ, et al. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of mpamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone. Transplantation, 2007,83 (6) : 809-814.
